keyword
MENU ▼
Read by QxMD icon Read
search

Long acting antipsychotics

keyword
https://www.readbyqxmd.com/read/29238631/ethnic-and-age-disparities-in-patients-taking-long-acting-injectable-atypical-antipsychotics
#1
Mateen Soleman, Nikki Lam, Benjamin K Woo
Introduction This study will determine whether different ethnicities and different age groups receive equal amounts of long-acting atypical antipsychotics in comparison to their oral equivalents. Methods Secondary analyses of data from the Los Angeles County Department of Health Services Electronic Health Record (total N=63,134 inpatient visits) were performed. Chi-squared statistics were used to compare ethnicity and age with the use of either risperidone injectable or paliperidone palmitate (r-LAIs) versus risperidone oral...
October 12, 2017: Curēus
https://www.readbyqxmd.com/read/29232310/comparison-of-paliperidone-palmitate-and-risperidone-long-acting-injection-in-schizophrenic-patients-results-from-a-multicenter-retrospective-cohort-study-in-france
#2
Frédéric Limosin, Drifa Belhadi, Denis Comet, Maud Pacou, Sophie Bouju, Kristel Van Impe, Pascal Guillon
PURPOSE/BACKGROUND: The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. METHODS: We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization...
December 11, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29187753/subchronic-olanzapine-exposure-leads-to-increased-expression-of-myelination-related-genes-in-rat-fronto-medial-cortex
#3
Kari M Ersland, Silje Skrede, Christine Stansberg, Vidar M Steen
Schizophrenia is a psychotic disorder with severe and disabling symptoms, such as hallucinations, delusions, blunted affect and social withdrawal. The neuropathology remains elusive, but disturbances in immunity-related processes, neuronal connectivity and myelination have consistently been linked to schizophrenia. Antipsychotic drugs can be efficient in reducing symptoms, acting primarily on the dopamine system, but additional biological targets are likely to exist. Here we have screened for novel mechanisms of action in an animal model, using adult rats exposed to long-acting olanzapine, achieving stable and clinically relevant antipsychotic drug concentrations...
November 30, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/29185542/pimavanserin-a-novel-therapeutic-option-for-parkinson-disease-psychosis
#4
REVIEW
Trevor Hawkins, Brian D Berman
Purpose of review: In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. Recent findings: Pimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms...
April 2017: Neurology. Clinical Practice
https://www.readbyqxmd.com/read/29179595/efficacy-and-safety-of-aripiprazole-lauroxil-once-monthly-versus-aripiprazole-once-monthly-long-acting-injectable-formulations-in-patients-with-acute-symptoms-of-schizophrenia-an-indirect-comparison-of-two-double-blind-placebo-controlled-studies
#5
Chris Cameron, Jacqueline Zummo, Dharmik Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for the treatment of schizophrenia. OBJECTIVE: To indirectly compare the safety and efficacy of AL and aripiprazole once-monthly (AOM). METHODS: We performed a systematic search to identify randomized, controlled trials of AOM and AL that met criteria for indirect comparison according to Bayesian network meta-analysis. The analysis indirectly compared AL and AOM treatment groups for efficacy by mean change in Positive and Negative Syndrome Scale (PANSS) total score and ≥30% reduction in PANSS total score, as well as tolerability including adverse events, akathisia, and weight gain...
November 27, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29179228/can-we-rely-on-agnp-therapeutic-targets-also-for-lai-antipsychotics
#6
Sara Baldelli, Emilio Clementi, Dario Cattaneo
The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines...
November 27, 2017: Pharmacopsychiatry
https://www.readbyqxmd.com/read/29177572/aripiprazole-lauroxil-a-review-in-schizophrenia
#7
James E Frampton
Aripiprazole lauroxil long-acting injectable (LAI) [Aristada®] is an intramuscularly administered, extended-release prodrug of aripiprazole, an established atypical antipsychotic agent that, in terms of its relative position within the class, is at the low end of the risk spectrum for metabolic side effects. In the USA, aripiprazole lauroxil LAI is indicated for the treatment of schizophrenia; approved doses of the drug can be injected once-monthly (q4w), every 6 weeks (q6w) or every 2 months (q8w). The efficacy of the 441 and 882 mg q4w dosages in the treatment of acute exacerbations of schizophrenia and as long-term maintenance therapy in stable schizophrenia has been directly demonstrated in a phase III clinical trial and extension, while the efficacy of the 662 mg q4w, 882 mg q6w and 1064 mg q8w dosing regimens has been established on the basis of pharmacokinetic bridging studies...
November 25, 2017: Drugs
https://www.readbyqxmd.com/read/29174738/symptoms-and-functioning-with-aripiprazole-once-monthly-injection-as-maintenance-treatment-for-bipolar-i-disorder
#8
Joseph R Calabrese, Raymond Sanchez, Na Jin, Joan Amatniek, Kevin Cox, Brian Johnson, Pamela Perry, Peter Hertel, Pedro Such, Robert D McQuade, Margaretta Nyilas, William H Carson
BACKGROUND: Effects of maintenance treatment with aripiprazole once-monthly 400mg (AOM 400) on symptoms and functioning were assessed in adults with bipolar I disorder (BP-I) after a manic episode. METHODS: Patients were stabilized on oral aripiprazole, cross-titrated to AOM 400, then randomized in a 52-week, double-blind, placebo-controlled, withdrawal phase. Prespecified secondary outcomes are reported: time to hospitalization for mood episode, Young Mania Rating Scale (YMRS), Montgomery-Åsberg Depression Rating Scale (MADRS), Clinical Global Impression-Bipolar scale, Functioning Assessment Short Test (FAST), and Brief Quality of Life in Bipolar Disorder questionnaire...
October 24, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29168261/-impact-of-drug-reimbursement-policies-on-prescribing-a-case-study-of-a-newly-marketed-long-acting-injectable-antipsychotics-among-relapsed-schizophrenia-patients
#9
John W Jackson, Lisa Fulchino, James Rogers, Helen Mogun, Jennifer Polinski, David C Henderson, Sebastian Schneeweiss, Michael A Fischer
OBJECTIVE: To quantify and explain variation in use of long-acting injectable antipsychotics (LAIs) in the United States, and understand the relationship between patient characteristics, drug reimbursement policies, and LAI prescribing after relapse. METHODS: A cohort of recently relapsed patients with schizophrenia ages 18 to 64, identified immediately after discharge from a related inpatient hospitalization, partial hospitalization, or emergency room visit, drawn from 2004 to 2006 Medicaid claims, and followed for 90 days until LAI initiation...
November 23, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/29165095/metabolic-syndrome-and-cardiovascular-risk-in-people-treated-with-long-acting-injectable-antipsychotics
#10
Vanessa Sanchez-Martinez, Dolores Romero-Rubio, Maria Jose Abad-Perez, Maria Amparo Descalzo-Cabades, Sofia Alonso-Gutierrez, Jose Salazar-Fraile, Vicente Montagud, Lorenzo Facila
BACKGROUND: People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs. OBJECTIVE: To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics...
November 20, 2017: Endocrine, Metabolic & Immune Disorders Drug Targets
https://www.readbyqxmd.com/read/29158676/role-of-3-monthly-long-acting-injectable-paliperidone-in-the-maintenance-of-schizophrenia
#11
REVIEW
Claudio Brasso, Silvio Bellino, Paola Bozzatello, Cristiana Montemagni, Paola Rocca
Aims: Paliperidone palmitate 3-month (PP3M) represents a new long-acting injectable antipsychotic therapeutic option. This review aims: 1) to summarize available data relating to efficacy, safety, tolerability and costs of PP3M; 2) to describe hospitalization rate, occupational status, treatment preference, satisfaction, adherence and caregiver burden of patients with schizophrenia who participate in PP3M clinical trials; 3) to examine ethical implications, pros and cons of PP3M use and 4) to propose study designs to further assess PP3M...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29141463/once-monthly-injection-of-paliperidone-palmitate-in-patients-with-recently-diagnosed-and-chronic-schizophrenia-a-post-hoc-comparison-of-efficacy-and-safety
#12
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan, Yu Feng
BACKGROUND: The use of long-acting injectable antipsychotics in recently diagnosed schizophrenia remains less explored. We evaluated the efficacy and safety of paliperidone palmitate once-monthly (PP1M) treatment in adult patients with recently diagnosed vs. chronic schizophrenia. RESEARCH DESIGN AND METHODS: These post-hoc analyses included two multicenter studies. Study 1 (NCT01527305) enrolled recently diagnosed (≤5 years) and chronic (>5 years) patients; Study 2 (NCT01051531) enrolled recently diagnosed patients only...
November 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29137178/antidepressants-and-mood-stabilizers-novel-research-avenues-and-clinical-insights-for-bipolar-depression
#13
REVIEW
In Hee Shim, Young Sup Woo, Moon-Doo Kim, Won-Myong Bahk
The concept of the bipolar-spectrum and of mixed features being a bridge between major depressive disorders and bipolar disorders (BDs) has become increasingly important in mood-disorder diagnoses. Under these circumstances, antidepressants (ADs) and mood stabilizers (MSs) should be used with caution in the treatment of major depressive episodes (MDEs) and to obtain long-term stability in BDs. Before treating MDEs, screening tools, specific symptom evaluation and medical history should be used to distinguish between bipolarity and mixed features in patients for whom AD monotherapy may present a risk...
November 13, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29070067/prescription-of-potentially-inappropriate-medications-among-older-people-with-intellectual-disability-a-register-study
#14
Anna Axmon, Magnus Sandberg, Gerd Ahlström, Patrik Midlöv
BACKGROUND: Older people have a greater disease burden and are more likely than younger to be prescribed medications. They are also more sensitive to adverse effects. With this in mind, a range of medications have been suggested inappropriate in this population. People with intellectual disability (ID) have a higher disease burden than the general population, putting them at even greater risk of prescription of such medications. The aim of this study was to describe prescription of potentially inappropriate medications among older people with ID in relation to prescriptions among their age peers in the general population...
October 25, 2017: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29065847/long-term-administration-of-antipsychotic-drugs-in-schizophrenia-and-influence-of-substance-and-drug-abuse-on-the-disease-outcome
#15
F-M Werner, Rafael Coveñas
BACKGROUND: Many schizophrenic patients with a long-term administration of antipsychotic drugs do not regularly adhere to the prescribed pharmacotherapy. Antipsychotic drugs constitute a palliative, but not a curative treatment, and the long-term effect of these drugs is not secure. Patients tend to consume nicotine and alcohol, as well as some patients consume drugs such as cannabis and amphetamines. OBJECTIVE: The objective of this mini-review is to examine the reasons for the high tendency of schizophrenic patients to consume alcohol, nicotine and drugs and in addition to suggest measures to reduce the abuse of substances and drugs...
October 20, 2017: Current Drug Abuse Reviews
https://www.readbyqxmd.com/read/29057674/all-cause-hospitalization-and-associated-costs-in-patients-with-schizophrenia-or-bipolar-disorder-initiating-long-acting-injectable-antipsychotics
#16
Tingjian Yan, Mallik Greene, Eunice Chang, Ann Hartry, Maëlys Touya, Michael S Broder
OBJECTIVE: To compare all-cause hospitalization and associated costs among patients with schizophrenia or bipolar disorder (BD) treated with long-acting injectable antipsychotics (LAIs). METHODS: Truven MarketScan® Medicaid claims database was used to identify patients with schizophrenia; MarketScan® Medicaid and commercial claims databases to identify BD. Adult patients with ≥1 LAI claim from 01/01/2013-06/30/2014 (ID period) were identified. The first day of LAI initiation was the index date; patients were followed for ≥1 year...
October 23, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/29047368/comparison-and-predictors-of-treatment-adherence-and-remission-among-patients-with-schizophrenia-treated-with-paliperidone-palmitate-or-atypical-oral-antipsychotics-in-community-behavioral-health-organizations
#17
Jeffrey P Anderson, Zeynep Icten, Veronica Alas, Carmela Benson, Kruti Joshi
BACKGROUND: Nonadherence to antipsychotic treatment increases the likelihood of relapse and progressive symptomatology in patients with schizophrenia. Atypical long-acting injectables, including paliperidone palmitate (PP), may increase adherence and improve symptoms. This study compared and assessed predictors of treatment patterns and symptom remission among schizophrenia patients treated with PP versus atypical oral antipsychotic therapy (OAT) in community behavioral health organizations (CBHOs)...
October 18, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/29047301/pimavanserin-novel-pharmacotherapy-for-parkinson-s-disease-psychosis
#18
Zeyad T Sahli, Frank I Tarazi
Pimavanserin is the first FDA-approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Areas covered: This review focuses on the preclinical discovery of pimavanserin. It analyzes the pharmacological, behavioral and molecular mechanisms of pimavanserin and their contribution to the therapeutic advantages of the drug as reported in published preclinical and clinical studies, press releases and product labels. Expert opinion: Pimavanserin exhibits a unique pharmacological profile with nanomolar affinity at serotonin 5-HT2A and 5-HT2C receptors...
October 31, 2017: Expert Opinion on Drug Discovery
https://www.readbyqxmd.com/read/29039277/is-paliperidone-palmitate-more-effective-than-other-long-acting-injectable-antipsychotics
#19
R Patel, E Chesney, M Taylor, D Taylor, P McGuire
BACKGROUND: Paliperidone palmitate is one of the most widely prescribed long-acting injectable (LAI) antipsychotics in the UK. However, it is relatively expensive and there are few data comparing its effectiveness to that of other LAI antipsychotics. We sought to address this issue by analyzing a large anonymized electronic health record (EHR) dataset from patients treated with LAI antipsychotics. METHODS: EHR data were obtained from 1281 patients in the South London and Maudsley NHS Foundation Trust (SLaM) who started treatment with a LAI antipsychotic between 1 April 2011 and 31 January 2015...
October 17, 2017: Psychological Medicine
https://www.readbyqxmd.com/read/29039241/aripiprazole-long-acting-injection-a-mirror-image-study-of-its-effects-on-hospitalisation-at-one-year
#20
David M Taylor, Anna Sparshatt, Fahima Amin, Ian Osborne, Olubanke Dzahini, Gwenllian Hughes, Catrin Fischetti
Second generation antipsychotic long-acting injections have a greater cost than older depots. Their cost-effectiveness has yet to be established. We conducted a non-interventional, observational, follow-up of patients prescribed aripiprazole long-acting injection in two centres using a mirror image method. Data were available for 160 patients consecutively prescribed aripiprazole long-acting injection, of whom 30 were not included in the analysis (21 forensic patients, five incomplete data and four lost to follow-up)...
October 1, 2017: Journal of Psychopharmacology
keyword
keyword
81198
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"